<DOC>
	<DOCNO>NCT02561546</DOCNO>
	<brief_summary>An open-labeled phase II study investigate preliminary efficacy use p53 gene therapy treatment diabetes concurrent hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>p53 Gene Therapy Treatment Diabetes Concurrent With Hepatocellular Carcinoma</brief_title>
	<detailed_description>It find treatment HCC use p53 gene therapy concurrent diabetes control well . The objective study investigate anti-diabetic anti-tumor role p53 gene therapy . This open-labeled , randomize , active-controlled phase 2 study . p53 inject via artery , supply blood tumor nodule . The study endpoints anti-diabetic role fast plasma glucose ( FPG ) , postprandial glucose ( PPG ) glycosylated hemoglobin ( A1C ) 30 day start treatment ; antitumor effect progression-free survival overall survival .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>histopathologically diagnose unresectable HCC 18 year old Eastern Cooperative Oncology Group ( ECOG ) score 02 Barcelona Clinic Liver Cancer ( BCLC ) Stage B C ChildPugh score A B ; normal test hemogram , blood coagulation , liver kidney function sign informed consent form . hypersensitive study drug With abnormal coagulation condition bleed disorder infection serious condition prevent use study treatment pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>concurrent</keyword>
</DOC>